Literature DB >> 15794398

Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization.

Bernard M J Uitdehaag1, Ludwig Kappos, Lars Bauer, Mark S Freedman, David Miller, Rupert Sandbrink, Chris H Polman.   

Abstract

The new McDonald diagnostic criteria for multiple sclerosis (MS) incorporate detailed criteria for the interpretation and classification of magnetic resonance imaging (MRI) findings, but, in contrast, provide no instructions for the interpretation of clinical findings. Because MS according to the McDonald criteria is one of the primary endpoints in a large trial enrolling patients after the first manifestation suggestive for a demyelinating disease (BENEFIT study), it was decided to organize a centralized eligibility assessment for this trial. During this eligibility assessment it was observed that there were marked inconsistencies in the decisions of participating neurologists with respect to the classification of clinical symptoms as being caused by one or more lesions provoking discussions in about one in every five patients. This paper describes these inconsistencies and their sources, and recommends a systematic approach that attempts to reduce the variability in interpreting clinical findings.

Entities:  

Mesh:

Year:  2005        PMID: 15794398     DOI: 10.1191/1352458505ms1149oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  9 in total

1.  [Revision of McDonald's new diagnostic criteria for multiple sclerosis].

Authors:  H Wiendl; B C Kieseier; R Gold; R Hohlfeld; M Bendszus; H-P Hartung
Journal:  Nervenarzt       Date:  2006-10       Impact factor: 1.214

2.  Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS.

Authors:  Jaume Sastre-Garriga; M Tintoré; C Nos; C Tur; J Río; N Téllez; J Castilló; A Horga; H Perkal; M Comabella; A Rovira; X Montalban
Journal:  J Neurol       Date:  2009-11-28       Impact factor: 4.849

Review 3.  The tension between early diagnosis and misdiagnosis of multiple sclerosis.

Authors:  Andrew J Solomon; John R Corboy
Journal:  Nat Rev Neurol       Date:  2017-08-11       Impact factor: 42.937

Review 4.  [Radiologically isolated syndrome: multiple sclerosis based solely on MRI findings?].

Authors:  J Sellner; L Schirmer; B Hemmer; M Mühlau
Journal:  Nervenarzt       Date:  2010-10       Impact factor: 1.214

5.  Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF.

Authors:  Jens Kuhle; Raija L P Lindberg; Axel Regeniter; Matthias Mehling; Francine Hoffmann; Markus Reindl; Thomas Berger; Ernst W Radue; David Leppert; Ludwig Kappos
Journal:  J Neurol       Date:  2007-02       Impact factor: 4.849

6.  Differential diagnosis of suspected multiple sclerosis: a consensus approach.

Authors:  D H Miller; B G Weinshenker; M Filippi; B L Banwell; J A Cohen; M S Freedman; S L Galetta; M Hutchinson; R T Johnson; L Kappos; J Kira; F D Lublin; H F McFarland; X Montalban; H Panitch; J R Richert; S C Reingold; C H Polman
Journal:  Mult Scler       Date:  2008-09-19       Impact factor: 6.312

7.  Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b.

Authors:  Chris Polman; Ludwig Kappos; Mark S Freedman; Gilles Edan; Hans-Peter Hartung; David H Miller; Xavier Montalbán; Frederick Barkhof; Krzysztof Selmaj; Bernard M J Uitdehaag; Susanne Dahms; Lars Bauer; Christoph Pohl; Rupert Sandbrink
Journal:  J Neurol       Date:  2007-11-15       Impact factor: 4.849

8.  MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome.

Authors:  Jessica M Nielsen; Christoph Pohl; Chris H Polman; Frederik Barkhof; Mark S Freedman; Gilles Edan; David H Miller; Lars Bauer; Rupert Sandbrink; Ludwig Kappos; Bernard M J Uitdehaag
Journal:  BMC Neurol       Date:  2009-05-20       Impact factor: 2.474

9.  Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.

Authors:  H Tedeholm; J Lycke; B Skoog; V Lisovskaja; J Hillert; C Dahle; J Fagius; S Fredrikson; A-M Landtblom; C Malmeström; C Martin; F Piehl; B Runmarker; L Stawiarz; M Vrethem; O Nerman; O Andersen
Journal:  Mult Scler       Date:  2012-11-01       Impact factor: 6.312

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.